A single-center, single-dose, randomized, three-way crossover phase I study comparing pharmacokinetics, safety and tolerability of two formulations of AP-CBD/THC, with Buccal Sativex in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Cannabidiol/tetrahydrocannabivarin-9 (Primary) ; Nabiximols
- Indications Pain
- Focus Adverse reactions
- 09 Aug 2017 Status changed from recruiting to completed, according to an Intec Pharma media release.
- 03 Aug 2017 Results published in an Intec Pharma media release.
- 22 Mar 2017 According to an Intec Pharma media release, topline results from this trial are expected in the third quarter of 2017.